BioAtla Announces 50-for-1 Share Consolidation

The move aims to regain Nasdaq compliance with $1 minimum bid price requirement

Mar. 31, 2026 at 10:30pm

Got story updates? Submit your updates here. ›

BioAtla, Inc., a global clinical-stage biotechnology company, announced that it will effect a 50-for-1 share consolidation of its common stock. The consolidation is intended to increase the per-share trading price of the stock and enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Why it matters

BioAtla's share consolidation is a common corporate action taken by companies to boost their stock price and maintain their listing on major exchanges. Maintaining a Nasdaq listing is crucial for biotechnology firms to access capital markets and raise funds for ongoing research and development.

The details

The share consolidation will take effect on April 6, 2026, with every 50 shares of BioAtla's common stock being automatically converted into 1 share. No fractional shares will be issued, and stockholders entitled to fractional shares will receive a cash payment instead. The company's outstanding stock options and warrants will also be proportionately adjusted.

  • The share consolidation will become effective on April 6, 2026 at 12:01 a.m. Eastern Time.
  • BioAtla's stockholders approved the share consolidation proposal at a special meeting on March 23, 2026.

The players

BioAtla, Inc.

A global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors.

BA Merger Sub, Inc.

BioAtla's wholly-owned subsidiary that will merge with and into BioAtla, with BioAtla surviving the merger.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

BioAtla's share consolidation is a strategic move to maintain its Nasdaq listing and access to capital markets, which is crucial for a clinical-stage biotechnology company to continue funding its research and development efforts.